RGNX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 Ready to Announce with Confidence?

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - March 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning the efficacy and safety of its RGX-111 trial study.

On January 28, 2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for the treatment of MPS II, also known as Hunter Syndrome, citing the similarities in products, study populations, and shared risk between the clinical studies."

On this news, REGENXBIO's stock price fell $2.40 per share, or 17.9%, to close at $11.01 per share on January 28, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding REGENXBIO's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the REGENXBIO class action, go to www.faruqilaw.com/RGNX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287818

Source: Faruqi & Faruqi LLP

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies in the Banking / Financial Services industry.

RGNX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

2026-03-09 6:28 PM EDT

SDM CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Smart Digital (SDM) Investors of Securities Class Action Deadline on March 16, 2026

2026-03-09 6:24 PM EDT

RR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Richtech Robotics (RR) Investors of Securities Class Action Deadline on April 3, 2026

2026-03-09 6:20 PM EDT

Dec 16, 2025

What makes a press release rise above the rest? We analyzed the most successful press releases of 2025 to see what caught attention and why. This year’s review looks at total views from human readers and AI systems across the top five hundred public company press releases distributed through TMX Newsfile in 2025. These views come from all of Newsfile’s general distribution channels, such as Yahoo and Apple. They reflect how audiences discovered and engaged with each announcement. Key Insights...

Litigation and Regulation

Banking / Financial Services